Article Dans Une Revue Vaccine Année : 2022

Pneumococcal and influenza vaccination coverage among at-risk adults: A 5-year French national observational study

Jérôme Fernandes
  • Fonction : Auteur
Nicolas Roche
Alexandre Vainchtock
  • Fonction : Auteur
Fanny Raguideau
Joannie Lortet-Tieulent
Emmanuelle Blanc
  • Fonction : Auteur
  • PersonId : 1111789
Jennifer Moïsi
  • Fonction : Auteur

Résumé

Introduction: The risk of developing pneumococcal infections increases with certain chronic conditions and in immunocompromised patients. We aimed to monitor pneumococcal vaccination coverage in at-risk patients and to examine factors associated with pneumococcal vaccination in France. Material and methods: In this annual cross-sectional study, at-risk patients were extracted between 2014 and 2018 from the National Health Insurance’s (NHI) General scheme’s claims database with their vaccine reimbursements. Descriptive analyses and a logistic model were performed to assess the influence of healthcare use and medical and demographic factors on pneumococcal vaccination. Results and discussion: In 2018, 4.5% of 4,045,021 at-risk adults were up to date with their pneumococcal vaccination. During the study period, the number of patients with chronic medical conditions (86% of 4,045,021) increased by 10.1%, but vaccination coverage decreased from 12.9% to 2.9%. The population with immunocompromised status (14% of 4,045,021) increased by 16.2% and vaccination coverage from 10.3% to 18.8%. Influenza vaccination coverage was much higher and stable (around 45.0%). Factors associated with pneumococcal vaccination were: immunocompromised status vs. having a chronic medical condition (odds ratio [OR] 4.72), influenza vaccination (OR 2.36–3.42), hepatitis B vaccination (OR 2.82), DTPolio vaccination (OR 1.52), ≥5 specialist physicians’ visits (OR 1.17), and age above 74 (OR 1.12). Pneumococcal vaccine dispensing was extremely low (median of 9 per GP,1 per specialist over 9 years) despite frequent healthcare visits. Conclusion: Pneumococcal and influenza vaccination coverage of adults at risk of pneumococcal disease fell well below public health expectations. Invitations for pneumococcal vaccination should be sent by the NHI to high-risk patients. Patient management protocols should include pneumococcal vaccination. Patients with multiple comorbidities are a high-priority population given the large potential health gains offered by pneumococcal vaccination. Commitment of both scientific societies and health authorities is urgently needed to increase vaccination coverage in at-risk populations.

Fichier principal
Vignette du fichier
2022 Wyplosz et al., Pneumococcal.pdf (37.99 Mo) Télécharger le fichier

Dates et versions

hal-03719216 , version 1 (11-07-2022)

Licence

Identifiants

Citer

Benjamin Wyplosz, Jérôme Fernandes, Ariane Sultan, Nicolas Roche, François Roubille, et al.. Pneumococcal and influenza vaccination coverage among at-risk adults: A 5-year French national observational study. Vaccine, 2022, 40 (33), pp.4911-4921. ⟨10.1016/j.vaccine.2022.06.071⟩. ⟨hal-03719216⟩
134 Consultations
64 Téléchargements

Altmetric

Partager

  • More